Shares of NeoGenomics (NASDAQ: NEO) jumped 53.9% this week, according to data from S&P Global Market Intelligence. The cancer diagnostic company's stock closed last Friday at $7.31 a share and then ...
Hosted on MSN
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a shocking sell-off after Chief Executive Chris Smith announced his retirement on Monday.
NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...
On Thursday, Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day.
NeoGenomics (NEO) has quietly strung together a solid rebound, with shares up roughly 44% over the past 3 months and about 16% this month, drawing fresh attention after a tough year. See our latest ...
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback